4.7 Article

The load of short telomeres, estimated by a new method, Universal STELA, correlates with number of senescent cells

期刊

AGING CELL
卷 9, 期 3, 页码 383-397

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1474-9726.2010.00568.x

关键词

abrupt shortening; aging; cancer; polymerase chain reaction; senescence; telomere

资金

  1. Vejle Hospital
  2. University of Southern Denmark
  3. Danish Aging Research Center

向作者/读者索取更多资源

P>Short telomeres are thought to trigger senescence, most likely through a single - or a group of few - critically shortened telomeres. Such short telomeres are thought to result from a combination of gradual linear shortening resulting from the end replication problem, reflecting the division history of the cell, superimposed by a more stochastic mechanism, suddenly causing a significant shortening of a single telomere. Previously, studies that have tried to explore the role of critically shortened telomeres have been hampered by methodological problems. With the method presented here, Universal STELA, we have a tool that can directly investigate the relationship between senescence and the load of short telomeres. The method is a variant of the chromosome-specific STELA method but has the advantage that it can demonstrate short telomeres regardless of chromosome. With Universal STELA, we find a strong correlation between the load of short telomeres and cellular senescence. Further we show that the load of short telomeres is higher in senescent cells compared to proliferating cells at the same passage, offering an explanation of premature cell senescence. This new method, Universal STELA, offers some advantages compared to existing methods and can be used to explore many of the unanswered questions in telomere biology including the role that telomeres play in cancer and aging.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell & Tissue Engineering

Generation of an induced pluripotent stem cell line (DANi-011A) from a Parkinson's disease patient with a LRRK2 p.G2019S mutation

Muwan Chen, Muyesier Maimaitili, Susanne Hvolbol Buchholdta, Uffe Birk Jensen, Fabia Febbraro, Mark Denham

STEM CELL RESEARCH (2020)

Article Genetics & Heredity

Deleterious mis-splicing of STK11 caused by a novel single-nucleotide substitution in the 3′ polypyrimidine tract of intron five

Thorkild Terkelsen, Ole H. Larsen, Soren Vang, Uffe B. Jensen, Friedrik Wikman

MOLECULAR GENETICS & GENOMIC MEDICINE (2020)

Article Multidisciplinary Sciences

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Juliette Coignard, Michael Lush, Jonathan Beesley, Tracy A. O'Mara, Joe Dennis, Jonathan P. Tyrer, Daniel R. Barnes, Lesley McGuffog, Goska Leslie, Manjeet K. Bolla, Muriel A. Adank, Simona Agata, Thomas Ahearn, Kristiina Aittomaeki, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Norbert Arnold, Kristan J. Aronson, Banu K. Arun, Annelie Augustinsson, Jacopo Azzollini, Daniel Barrowdale, Caroline Baynes, Heko Becher, Marina Bermisheva, Leslie Bernstein, Katarzyna Bialkowska, Carl Blomqvist, Stig E. Bojesen, Bernardo Bonanni, Ake Borg, Hiltrud Brauch, Hermann Brenner, Barbara Burwinkel, Saundra S. Buys, Trinidad Caldes, Maria A. Caligo, Daniele Campa, Brian D. Carter, Jose E. Castelao, Jenny Chang-Claude, Stephen J. Chanock, Wendy K. Chung, Kathleen B. M. Claes, Christine L. Clarke, J. Margriet Collee, Don M. Conroy, Kamila Czene, Mary B. Daly, Peter Devilee, Orland Diez, Yuan Chun Ding, Susan M. Domchek, Thilo Dork, Isabel dos-Santos-Silva, Alison M. Dunning, Miriam Dwek, Diana M. Eccles, A. Heather Eliassen, Christoph Engel, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Henrik Flyger, Florentia Fostira, Eitan Friedman, Lin Fritschi, Debra Frost, Manuela Gago-Dominguez, Susan M. Gapstur, Judy Garber, Vanesa Garcia-Barberan, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Mia M. Gaudet, Simon A. Gayther, Andrea Gehrig, Vassilios Georgoulias, Graham G. Giles, Andrew K. Godwin, Mark S. Goldberg, David E. Goldgar, Anna Gonzalez-Neira, Mark H. Greene, Pascal Guenel, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Patricia A. Harrington, Steven N. Hart, Wei He, Frans B. L. Hogervorst, Antoinette Hollestelle, John L. Hopper, Darling J. Horcasitas, Peter J. Hulick, David J. Hunter, Evgeny N. Imyanitov, Agnes Jager, Anna Jakubowska, Paul A. James, Uffe Birk Jensen, Esther M. John, Michael E. Jones, Rudolf Kaaks, Pooja Middha Kapoor, Beth Y. Karlan, Renske Keeman, Elza Khusnutdinova, Johanna I. Kiiski, Yon-Dschun Ko, Veli-Matti Kosma, Peter Kraft, Allison W. Kurian, Yael Laitman, Diether Lambrechts, Loic Le Marchand, Jenny Lester, Fabienne Lesueur, Tricia Lindstrom, Adria Lopez-Fernandez, Jennifer T. Loud, Craig Luccarini, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, John W. M. Martens, Noura Mebirouk, Alfons Meindl, Austin Miller, Roger L. Milne, Marco Montagna, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Finn C. Nielsen, Katie M. O'Brien, Olufunmilayo I. Olopade, Janet E. Olson, Hakan Olsson, Ana Osorio, Laura Ottini, Tjoung-Won Park-Simon, Michael T. Parsons, Inge Sokilde Pedersen, Beth Peshkin, Paolo Peterlongo, Julian Peto, Paul D. P. Pharoah, Kelly-Anne Phillips, Eric C. Polley, Bruce Poppe, Nadege Presneau, Miquel Angel Pujana, Kevin Punie, Paolo Radice, Johanna Rantala, Muhammad U. Rashid, Gad Rennert, Hedy S. Rennert, Mark Robson, Atocha Romero, Maria Rossing, Emmanouil Saloustros, Dale P. Sandler, Regina Santella, Maren T. Scheuner, Marjanka K. Schmidt, Gunnar Schmidt, Christopher Scott, Priyanka Sharma, Penny Soucy, Melissa C. Southey, John J. Spinelli, Zoe Steinsnyder, Jennifer Stone, Dominique Stoppa-Lyonnet, Anthony Swerdlow, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Mary Beth Terry, Alex Teule, Darcy L. Thull, Marc Tischkowitz, Amanda E. Toland, Diana Torres, Alison H. Trainer, Therese Truong, Nadine Tung, Celine M. Vachon, Ana Vega, Joseph Vijai, Qin Wang, Barbara Wappenschmidt, Clarice R. Weinberg, Jeffrey N. Weitzel, Camilla Wendt, Alicja Wolk, Siddhartha Yadav, Xiaohong R. Yang, Drakoulis Yannoukakos, Wei Zheng, Argyrios Ziogas, Kristin K. Zorn, Sue K. Park, Mads Thomassen, Kenneth Offit, Rita K. Schmutzler, Fergus J. Couch, Jacques Simard, Georgia Chenevix-Trench, Douglas F. Easton, Nadine Andrieu, Antonis C. Antoniou

Summary: Breast cancer risk for BRCA1/BRCA2 mutation carriers varies based on genetic factors. A case-only genome-wide association study identified novel loci associated with breast cancer risk for BRCA1/BRCA2 mutation carriers.

NATURE COMMUNICATIONS (2021)

Article Public, Environmental & Occupational Health

A Search for Undiagnosed Charcot-Marie-Tooth Disease Among Patients Registered with Unspecified Polyneuropathy in the Danish National Patient Registry

Signe Vaeth, Henning Andersen, Rikke Christensen, Uffe Birk Jensen

Summary: This study revealed that undiagnosed CMT patients can be identified in the DNPR, and it reported the number of possible CMT cases. The results suggest that the true prevalence of CMT may be higher than previously reported.

CLINICAL EPIDEMIOLOGY (2021)

Article Genetics & Heredity

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Inge M. M. Lakeman, Alexandra J. van den Broek, Julien A. M. Vos, Daniel R. Barnes, Julian Adlard, Irene L. Andrulis, Adalgeir Arason, Norbert Arnold, Banu K. Arun, Judith Balmana, Daniel Barrowdale, Javier Benitez, Ake Borg, Trinidad Caldes, Maria A. Caligo, Wendy K. Chung, Kathleen B. M. Claes, J. Margriet Collee, Fergus J. Couch, Mary B. Daly, Joe Dennis, Mallika Dhawan, Susan M. Domchek, Ros Eeles, Christoph Engel, D. Gareth Evans, Lidia Feliubadalo, Lenka Foretova, Eitan Friedman, Debra Frost, Patricia A. Ganz, Judy Garber, Simon A. Gayther, Anne-Marie Gerdes, Andrew K. Godwin, David E. Goldgar, Eric Hahnen, Christopher R. Hake, Ute Hamann, Frans B. L. Hogervorst, Maartje J. Hooning, John L. Hopper, Peter J. Hulick, Evgeny N. Imyanitov, Claudine Isaacs, Louise Izatt, Anna Jakubowska, Paul A. James, Ramunas Janavicius, Uffe Birk Jensen, Yue Jiao, Esther M. John, Vijai Joseph, Beth Y. Karlan, Carolien M. Kets, Irene Konstantopoulou, Ava Kwong, Clementine Legrand, Goska Leslie, Fabienne Lesueur, Jennifer T. Loud, Jan Lubinski, Siranoush Manoukian, Lesley McGuffog, Austin Miller, Denise Molina Gomes, Marco Montagna, Emmanuelle Mouret-Fourme, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Joanne Ngeow Yuen Yie, Edith Olah, Olufunmilayo I. Olopade, Sue K. Park, Michael T. Parsons, Paolo Peterlongo, Marion Piedmonte, Paolo Radice, Johanna Rantala, Gad Rennert, Harvey A. Risch, Rita K. Schmutzler, Priyanka Sharma, Jacques Simard, Christian F. Singer, Zsofia Stadler, Dominique Stoppa-Lyonnet, Christian Sutter, Yen Yen Tan, Manuel R. Teixeira, Soo Hwang Teo, Alex Teule, Mads Thomassen, Darcy L. Thull, Marc Tischkowitz, Amanda E. Toland, Nadine Tung, Elizabeth J. van Rensburg, Ana Vega, Barbara Wappenschmidt, Peter Devilee, Christi J. van Asperen, Jonine L. Bernstein, Kenneth Offit, Douglas F. Easton, Matti A. Rookus, Georgia Chenevix-Trench, Antonis C. Antoniou, Mark Robson, Marjanka K. Schmidt

Summary: The study found that different PRS313 were associated with contralateral breast cancer risk for BRCA1 and BRCA2 heterozygotes. Adjusting for various factors did not change the association effect sizes. For women with first BC diagnosis < age 40, the 10-year CBC risks for BRCA1 and BRCA2 heterozygotes were 22% and 32%, 13% and 23% respectively.

GENETICS IN MEDICINE (2021)

Article Oncology

Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study

Mark A. Jenkins

Summary: The study identified significant familial risk factors affecting colorectal cancer risk for Lynch syndrome carriers, resulting in a wide variation in risk between carriers of the same gene. This highlights the importance of personalized risk assessments for precision prevention and early detection of colorectal cancer in individuals with Lynch syndrome.

LANCET ONCOLOGY (2021)

Article Genetics & Heredity

Mono-allelic loss of YTHDF3 and neurodevelopmental disorder: clinical features of four individuals with 8q12.3 deletions

Thorkild Terkelsen, Charlotte Brasch-Andersen, Niels Illum, Tiffany Busa, Chantal Missirian, Kate Chandler, Simon T. Holden, Uffe Birk Jensen, Christina R. Fagerberg

Summary: Deletion of the YTHDF3 gene can cause a neurodevelopmental disorder characterized by developmental delay and intellectual disability, with common features including a young age group (4-22 years).

CLINICAL GENETICS (2022)

Article Genetics & Heredity

Clinical implications of genetic testing in familial intermediate and late-onset colorectal cancer

Malene Djursby, Thomas van Overeem Hansen, Karin A. W. Wadt, Majbritt Busk Madsen, Lukas Adrian Berchtold, Charlotte Kvist Lautrup, Sara Markholt, Uffe Birk Jensen, Lotte Nylandsted Krogh, Malene Lundsgaard, Anne Marie Gerdes, Mef Nilbert, Christina Therkildsen

Summary: The genetic background of familial, late-onset colorectal cancer is not well studied, and the contribution of known or suggested CRC predisposition genes to late-onset CRC is still unclear. In this study, pathogenic variants were identified in MSH6, MUTYH, and NTHL1 genes, while variants of unknown significance were found in MSH6. Screening using a comprehensive cancer gene panel in families with late-onset CRC does not have significant clinical value. Only patients with abnormal MMR immunohistochemistry or microsatellite instability, suggestive of Lynch syndrome, or a family history indicating another cancer predisposition syndrome should be prioritized for genetic evaluations. The presence of variants in MSH6 and MUTYH genes suggests the involvement of complex inheritance patterns in late-onset CRC.

HUMAN GENETICS (2022)

Article Immunology

Novel homozygous CD46 variant with C-isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome

Vivien R. Schack, Morten K. Herlin, Henrik Pedersen, J. Magnus Bernth Jensen, Mia Faerch, Bettina Bundgaard, Rasmus K. Jensen, Uffe B. Jensen, Rikke Christensen, Gregers R. Andersen, Steffen Thiel, Per Hollsberg

Summary: We report a pediatric patient with aHUS carrying a previously unreported homozygous variant in CD46. Functional analyses showed that this variant caused complement dysregulation through multiple mechanisms. These findings highlight the coexistence of multiple mechanisms that may disrupt CD46 function during aHUS development.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Article Genetics & Heredity

Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach

Mads Thomassen, Romy L. S. Mesman, Thomas V. O. Hansen, Mireia Menendez, Maria Rossing, Ada Esteban-Sanchez, Emma Tudini, Therese Torngren, Michael T. Parsons, Inge S. Pedersen, Soo H. Teo, Torben A. Kruse, Pal Moller, Ake Borg, Uffe B. Jensen, Lise L. Christensen, Christian F. Singer, Daniela Muhr, Marta Santamarina, Rita Brandao, Brage S. Andresen, Bing-Jian Feng, Daffodil Canson, Marcy E. Richardson, Rachid Karam, Tina Pesaran, Holly LaDuca, Blair R. Conner, Nelly Abualkheir, Lily Hoang, Fabienne M. G. R. Calleja, Lesley Andrews, Paul A. James, Dave Bunyan, Amanda Hamblett, Paolo Radice, David E. Goldgar, Logan C. Walker, Christoph Engel, Kathleen B. M. Claes, Eva Machackova, Diana Baralle, Alessandra Viel, Barbara Wappenschmidt, Conxi Lazaro, Ana Vega, Maaike P. G. Vreeswijk, Miguel de la Hoya, Amanda B. Spurdle

Summary: Skipping of BRCA2 exon 3 is a naturally occurring splicing event that complicates the clinical classification of related variants. This study used multiple evidence types to assess the pathogenicity of these variants and identified six loss-of-function mutations. The study also highlights the value of using a points-based approach for variant classification and the importance of considering cryptic splice site usage.

HUMAN MUTATION (2022)

Article Multidisciplinary Sciences

Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes

Nanna Baek Moller, Desiree Sofie Boonen, Elisabeth Simone Feldner, Qin Hao, Martin Larsen, Anne-Vibeke Laenkholm, Ake Borg, Anders Kvist, Therese Torngren, Uffe Birk Jensen, Susanne Eriksen Boonen, Mads Thomassen, Thorkild Terkelsen

Summary: BOADICEA is a comprehensive risk prediction model for breast and/or ovarian cancer and for carrying pathogenic variants in cancer susceptibility genes. A retrospective study was conducted to validate the model's predictions for these genes using data from 2033 individuals in Denmark. The model performed well in predicted likelihood sub-categories and had acceptable calibration and discrimination.

SCIENTIFIC REPORTS (2023)

Article Genetics & Heredity

Lack of guidelines and translational knowledge is hindering the implementation of psychiatric genetic counseling and testing within Europe-A multi-professional survey study

Kati Koido, Charlotta Ingvoldstad Malmgren, Lejla Pojskic, Peter Z. Almos, Sarah E. Bergen, Isabella Borg, Nada Bozina, Domenico A. Coviello, Franziska Degenhardt, Lana Ganoci, Uffe B. Jensen, Louise Durand-Lennad, Claudine Laurent-Levinson, Andrew McQuillin, Alvydas Navickas, Nikolai P. Pace, Milena Paneque, Marcella Rietschel, Maria Grigoroiu-Serbanescu, Maria Johansson Soller, Jaana Suvisaari, Algirdas Utkus, Evelien Van Assche, Lily Vissouze, Shachar Zuckerman, Boris Chaumette, Kristiina Tammimies

Summary: Genetic research has identified many genetic variants associated with neurodevelopmental disorders and major psychiatric disorders. However, there is a lack of knowledge and guidelines for psychiatric genetic testing and genetic counseling. A pan-European online survey reveals that 65.2% of respondents offer genetic testing for individuals with neurodevelopmental disorders, while only 26.5% offer it for individuals with major psychiatric disorders.

EUROPEAN JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

Daniel R. Barnes, Valentina Silvestri, Goska Leslie, Lesley McGuffog, Joe Dennis, Xin Yang, Julian Adlard, Bjarni A. Agnarsson, Munaza Ahmed, Kristiina Aittomaki, Irene L. Andrulis, Adalgeir Arason, Norbert Arnold, Bernd Auber, Jacopo Azzollini, Judith Balmana, Rosa B. Barkardottir, Daniel Barrowdale, Julian Barwell, Muriel Belotti, Javier Benitez, Pascaline Berthet, Susanne E. Boonen, Ake Borg, Aniko Bozsik, Angela F. Brady, Paul Brennan, Carole Brewer, Joan Brunet, Agostino Bucalo, Saundra S. Buys, Trinidad Caldes, Maria A. Caligo, Ian Campbell, Hayley Cassingham, Lise Lotte Christensen, Giulia Cini, Kathleen B. M. Claes, Jackie Cook, Anna Coppa, Laura Cortesi, Giuseppe Damante, Esther Darder, Rosemarie Davidson, Miguel de la Hoya, Kim De Leeneer, Robin de Putter, Jesus Del Valle, Orland Diez, Yuan Chun Ding, Susan M. Domchek, Alan Donaldson, Jacqueline Eason, Ros Eeles, Christoph Engel, D. Gareth Evans, Lidia Feliubadalo, Florentia Fostira, Megan Frone, Debra Frost, David Gallagher, Andrea Gehrig, Sophie Giraud, Gord Glendon, Andrew K. Godwin, David E. Goldgar, Mark H. Greene, Helen Gregory, Eva Gross, Eric Hahnen, Ute Hamann, Thomas V. O. Hansen, Helen Hanson, Julia Hentschel, Judit Horvath, Louise Izatt, Angel Izquierdo, Paul A. James, Ramunas Janavicius, Uffe Birk Jensen, Oskar Th Johannsson, Esther M. John, Gero Kramer, Lone Kroeldrup, Torben A. Kruse, Charlotte Lautrup, Conxi Lazaro, Fabienne Lesueur, Adria Lopez-Fernandez, Phuong L. Mai, Siranoush Manoukian, Zoltan Matrai, Laura Matricardi, Kara N. Maxwell, Noura Mebirouk, Alfons Meindl, Marco Montagna, Alvaro N. Monteiro, Patrick J. Morrison, Taru A. Muranen, Alex Murray, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Tu Nguyen-Dumont, Dieter Niederacher, Edith Olah, Olufunmilayo Olopade, Domenico Palli, Michael T. Parsons, Inge Sokilde Pedersen, Bernard Peissel, Pedro Perez-Segura, Paolo Peterlongo, Annabeth H. Petersen, Pedro Pinto, Mary E. Porteous, Caroline Pottinger, Miquel Angel Pujana, Paolo Radice, Juliane Ramser, Johanna Rantala, Mark Robson, Mark T. Rogers, Karina Ronlund, Andreas Rump, Ana Maria Sanchez de Abajo, Payal D. Shah, Saba Sharif, Lucy E. Side, Christian F. Singer, Zsofia Stadler, Linda Steele, Dominique Stoppa-Lyonnet, Christian Sutter, Yen Yen Tan, Manuel R. Teixeira, Alex Teule, Darcy L. Thull, Marc Tischkowitz, Amanda E. Toland, Stefania Tommasi, Angela Toss, Alison H. Trainer, Vishakha Tripathi, Virginia Valentini, Christi J. van Asperen, Marta Venturelli, Alessandra Viel, Joseph Vijai, Lisa Walker, Shan Wang-Gohrke, Barbara Wappenschmidt, Anna Whaite, Ines Zanna, Kenneth Offit, Mads Thomassen, Fergus J. Couch, Rita K. Schmutzler, Jacques Simard, Douglas F. Easton, Georgia Chenevix-Trench, Antonis C. Antoniou, Laura Ottini

Summary: The study assessed the associations of polygenic risk scores with breast and prostate cancer risks for male BRCA1 and BRCA2 carriers, finding strong associations between the risk scores and the respective cancer risks. The estimated breast cancer odds ratios were larger after adjusting for family history of female relative breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

The CRISPR/Cas9 Minipig-A Transgenic Minipig to Produce Specific Mutations in Designated Tissues

Martin Fogtmann Berthelsen, Maria Riedel, Huiqiang Cai, Soren H. Skaarup, Aage K. O. Alstrup, Frederik Dagnaes-Hansen, Yonglun Luo, Uffe B. Jensen, Henrik Hager, Ying Liu, Henrik Callesen, Mikkel H. Vendelbo, Jannik E. Jakobsen, Martin Kristian Thomsen

Summary: Research in large animal models has been simplified by the discovery of the CRISPR/Cas system, allowing for easier introduction of new gene alterations. A Cas9 minipig was cloned to generate a porcine model for pre-clinical research, with successful backcrossing and in vitro gene alterations confirmed. The development of a transgenic Cas9 minipig enables the creation of complex pre-clinical models for cancer research, including multiple gene alterations and in vivo activation of Cas9 expression.

CANCERS (2021)

暂无数据